Search research articles
Contact Us
Filters
Showing results (41-50 of 76) with videos related to
Page
of 8
Sort By:
Molecular Cancer Therapeutics
|
May 15, 2020
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia
Xiangmeng Wang, Po Yee Mak, Hong Mu, et al.
Journal of Hematology & Oncology
|
November 26, 2016
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
Xiaoying Lan, Chong Zhao, Xin Chen, et al.
Blood
|
November 3, 2010
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML
Bing Z Carter, Yi Hua Qiu, Nianxiang Zhang, et al.
Blood
|
April 20, 2002
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
Michele Milella, Zeev Estrov, Steven M Kornblau, et al.
Journal of Translational Medicine
|
March 21, 2021
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
Xuejie Jiang, Ling Jiang, Jiaying Cheng, et al.
Oncotarget
|
March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network
Bing Z Carter, Po Yee Mak, Ye Chen, et al.
Blood Advances
|
November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML
Neil Beeharry, Sean Landrette, Sophia Gayle, et al.
Haematologica
|
November 6, 2025
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1
Valerio Ciaurro, Vassilena Sharlandjieva, Anna Skwarska, et al.
Oncotarget
|
September 19, 2015
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Xuejie Jiang, Zhixiang Wang, Bingjie Ding, et al.
Science Translational Medicine
|
September 9, 2016
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z Carter, Po Yee Mak, Hong Mu, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 76) with videos related to
Sort By:
Page
of 8
Molecular Cancer Therapeutics
|
May 15, 2020
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia
Xiangmeng Wang, Po Yee Mak, Hong Mu, et al.
Journal of Hematology & Oncology
|
November 26, 2016
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
Xiaoying Lan, Chong Zhao, Xin Chen, et al.
Blood
|
November 3, 2010
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML
Bing Z Carter, Yi Hua Qiu, Nianxiang Zhang, et al.
Blood
|
April 20, 2002
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
Michele Milella, Zeev Estrov, Steven M Kornblau, et al.
Journal of Translational Medicine
|
March 21, 2021
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
Xuejie Jiang, Ling Jiang, Jiaying Cheng, et al.
Oncotarget
|
March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network
Bing Z Carter, Po Yee Mak, Ye Chen, et al.
Blood Advances
|
November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML
Neil Beeharry, Sean Landrette, Sophia Gayle, et al.
Haematologica
|
November 6, 2025
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1
Valerio Ciaurro, Vassilena Sharlandjieva, Anna Skwarska, et al.
Oncotarget
|
September 19, 2015
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Xuejie Jiang, Zhixiang Wang, Bingjie Ding, et al.
Science Translational Medicine
|
September 9, 2016
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z Carter, Po Yee Mak, Hong Mu, et al.
Page
of 8